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ABSTRACT
Autophagy is a conserved lysosomal degradation process that has important roles in both normal human physiology and disease.
However, the function of autophagy in bone homeostasis is not well understood. Here, we report that autophagy is activated during
osteoblast differentiation. Ablation of focal adhesion kinase family interacting protein of 200 kD (FIP200), an essential component of
mammalian autophagy, led to multiple autophagic defects in osteoblasts including aberrantly increased p62 expression, deﬁcient LC3‐
II conversion, defective autophagy ﬂux, absence of GFP‐LC3 puncta in FIP200‐null osteoblasts expressing transgenic GFP‐LC3, and
absence of autophagosome‐like structures by electron microscope examination. Osteoblast‐speciﬁc deletion of FIP200 led to
osteopenia in mice. Histomorphometric analysis revealed that the osteopenia was the result of cell‐autonomous effects of FIP200
deletion on osteoblasts. FIP200 deletion led to defective osteoblast terminal differentiation in both primary bone marrow and calvarial
osteoblasts in vitro. Interestingly, both proliferation and differentiation were not adversely affected by FIP200 deletion in early cultures.
However, FIP200 deletion led to defective osteoblast nodule formation after initial proliferation and differentiation. Furthermore,
treatment with autophagy inhibitors recapitulated the effects of FIP200 deletion on osteoblast differentiation. Taken together, these
data identify FIP200 as an important regulator of bone development and reveal a novel role of autophagy in osteoblast function
through its positive role in supporting osteoblast nodule formation and differentiation. © 2013 American Society for Bone and Mineral
Research.
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Introduction
Autophagy is the primary intracellular degradation system.During autophagy, cytoplasmic materials are enclosed in a
double‐membraned structure, autophagosome, which will fuse
with lysosome to form autolysosome, where degradation of the
cytoplasmic materials occurs. Autophagy can be induced by
starvation and other stresses to serve as a dynamic recycling
system that produces new building blocks and energy for cellular
renovation and homeostasis.(1) Besides its roles in adaptive
responses to starvation, quality control of intracellular proteins
and organelles, anti‐aging, suppression of tumor formation,
elimination of intracellular microbes, and antigen presentation,
there is increasing evidence showing that autophagy also
plays important roles in differentiation and development.(2,3)
In mammals, autophagy is important for preimplantation
development,(4) survival during neonatal starvation,(5) and cell
differentiation during erythropoiesis,(6–8) lymphopoeisis,(9–12)
and adipogenesis.(13–15)
The physiological and pathological roles of autophagy
have been described for many organs.(1,16) However, the role
of autophagy in bone is not well understood.(1,17) Osteoclasts,
osteoblasts, and osteocytes are the three major bone cell types
that are responsible for the maintenance of bone homeostasis.
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There is emerging evidence implicating autophagy as an
important mediator of bone cell function in normal physiology
and pathology.(17–21) Recent studies suggest that autophagic
mechanisms are active in osteocytes.(19,22–24) However, there is
limited data to explain the physiological roles of autophagy in
osteocyte homeostasis and skeletal maintenance.(17) A recent
study elegantly demonstrated that some essential autophagy
proteins, including Atg5, Atg7, Atg4B, and LC3, are important for
generating the osteoclast rufﬂed border and bone resorption
without affecting osteoclast differentiation.(25) This ﬁnding
clearly links the autophagy genes with skeletal homeostasis.
However, it is unclear whether the autophagy role of these
proteins contributes directly to the aforementioned functions.
The role of autophagy and/or autophagy proteins in osteoblast
function is the least studied among the three major bone cell
types. The closest clue came from the study of Nbr1, a selective
autophagic receptor for degradation of ubiquitinated substrates.
It has been shown that truncation of Nbr1 in a murine model,
where it can interact with p62 but not LC3, leads to increased
osteoblast differentiation and activity in vivo.(26) This study
suggests the participation of autophagy in osteoblast function.
Of note, Nbr1 is truncated globally but not osteoblast‐speciﬁcally
in this mouse model, which makes it unclear about the
particular dependence of osteoblasts on autophagy. Thus,
the direct roles of autophagy in osteoblast function are
still unknown. In particular, it is currently unknown to what
extent autophagy regulates osteoblast differentiation and bone
development.
Focal adhesion kinase family interacting protein of 200 kD
(FIP200) was initially identiﬁed as a protein inhibitor of focal
adhesion kinase and its related kinase Pyk2.(27,28) Subsequent
studies demonstrated that FIP200 also plays a role in the
regulation of diverse cellular functions including cell size,
survival, proliferation, spreading, and migration through its
interaction with multiple cellular proteins.(29) Recently, several
groups identiﬁed FIP200 as a component of the ULKs‐Atg13‐
FIP200 complex, which is essential for the induction of
autophagy in mammalian cells.(30–33) We showed that the
defective phenotypes in mice with FIP200 conditional knockout
in neurons(34) and hematopoietic stem cells(35) overlapped with
those observed inmutant mice with deletion of other autophagy
genes (eg, Atg5 and Atg7) in these tissues.(8,36–39) Moreover, our
recent studies demonstrated that suppression of autophagy by
FIP200 deletion inhibits mammary tumorigenesis,(40) impairs
DNA damage repair,(41) and depletes the postnatal neural stem
cell pool.(42)
In this study, the observation that osteoblasts had high
autophagy activity during nodule formation and differentiation
in vitro led us to investigate the in vivo function of osteoblast
autophagy. Because FIP200 global knockout leads to early
embryonic lethality in mice,(43) we generated osteoblast‐speciﬁc
FIP200 conditional knockout mice to study the role of autophagy
in bone development. Our data demonstrate that suppression
of autophagy in osteoblasts by FIP200 deletion leads to
compromised bone mass acquisition and osteoblast terminal
differentiation. These results provide clear evidence for a
positive role of autophagy in bone development and osteoblast
differentiation.
Materials and Methods
Mice and skeleton preparation
The ﬂoxed FIP200 (FIP200F/F), Osx‐Cre, Col3.6‐Cre, Col2.3‐Cre, and
GFP‐LC3 transgenic mice were described previously.(43–46) All
mice were backcrossed for at least eight generations onto a
C57BL/6 background. FIP200F/F mice were mated with Osx‐Cre,
Col3.6‐Cre, and Col2.3‐Cre mice to generate FIP200F/F;Osx‐Cre,
FIP200F/F;Col3.6‐Cre, and FIP200F/F;Col2.3‐Cre mice, designated
as Osx‐CKO, Col3.6‐CKO, and Col2.3‐CKO, respectively. Osx‐CKO
mice were further matedwith GFP‐LC3mice to generate FIP200F/
F;Osx‐Cre;GFP‐LC3 mice, designated as Osx‐CKO;GFP‐LC3 mice.
FIP200F/F mice and FIP200F/F;GFP‐LC3 mice served as control
mice for Osx‐CKOmice and Osx‐CKO;GFP‐LC3 mice, respectively.
C57BL/6 mice (Charles River, Wilmington, MA, USA) served as
wild‐type control for Osx‐Cre mice. Mice were housed under
pathogen‐free conditions, fed with 5001 or 5008 (for mating
units) rodent diet (LabDiet, St. Louis, MO, USA) and handled
according to local, state, and federal regulation. All experimental
procedureswere carried outwith the approval of the Institutional
Animal Care and Use Committee at the University of Michigan.
Mice were euthanized by carbon dioxide overdose at 1 month, 2
months, 6 months, and 1 year old for bone phenotyping studies
and at 6 to 8 weeks old for bone marrow cultures. Neonatal mice
were euthanized by decapitation in primary calvarial osteoblast
digestion experiments. The body weight of FIP200F/F and Osx‐
CKO mice were measured at birth, 1 week, 2 weeks, 1 month, 2
months, 3 months, 4 months, 5 months, 6 months, and 1 year
(only for male) of age. Mice genotyping for FIP200 and Cre alleles
were performed by polymerase chain reaction analysis of tail
DNA as described previously.(35) Skeleton preparation with
neonatalmicewas performed as described previously.(47) In brief,
after removal of the skin, viscera, and liver, themice were ﬁxed in
95% ethanol overnight and then stained in 0.15% Alcian Blue
solution overnight, followed by 2 to 5 hours 95% ethanol
treatment. Subsequently, the samples will be treated with 2%
KOH for 24 hours or longer and then stained in 1% KOH, 0.015%
Alizarin Red overnight. Skeletons will be cleared in 1% KOH, 20%
glycerol for 2 days or more, and stored in a 1:1mixture of glycerol
and 95% ethanol.
Micro‐computed tomography (micro‐CT) analysis
Femurs and third lumbar (L3) vertebrae (endochondral bone)
were dissected free of soft tissue and analyzed by micro‐CT
using an eXplore Locus SP (GE Healthcare Pre‐Clinical Imaging,
London, ON, Canada) as described previously.(48–50) In brief,
femurs were scanned using the Parker method of rotation at 80
kVp and 80mA and added ﬁltration in the form of both an acrylic
beam ﬂattener and a 0.02‐inch aluminum ﬁlter. Images were
reconstructed at an isotropic voxel size of 18mm (femora) and
16mm (vertebrae) and calibrated daily (before scanning) using a
phantom for densitometry. The metaphyseal/trabecular region
of interest (ROI) from the distal femora is identiﬁed starting at
the interface between the growth plate and metaphyseal
trabecular bone and extending 10% of the bone length into the
metaphysis using a splining algorithm in the transverse plane
(MicroView v2.2, GE Healthcare Pre‐Clinical Imaging). Trabecular
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region of interest from the LC3 vertebrae is manually segregated
from cortical bone by splining an areal region of interest at
multiple levels and then interpolating among these to generate
a volume of interest for the trabecular bone. Trabecular bone
volume fraction (BV/TV), thickness (TbTh), number (TbN), and
spacing (TbSp) were calculated after applying a constant
threshold. For cortical analysis, a diaphyseal region of interest
is identiﬁed using 18% of the bone length located in the center
of the diaphysis of the femur and corresponding precisely to the
location of the midpoint of the four‐point bending loads that
will be applied for mechanical testing. Cortical thickness and
endosteal and periosteal perimeters were then calculated after
applying a uniform threshold. Beam hardening (particularly in
the cortical regions) is minimized by the combination of the
beam ﬂattener and aluminum ﬁlter.(51)
Calvaria thickness measurement
Calvaria (intramembranous bone) thickness wasmeasured at the
center of parietal bone with Pﬁngst Original Iwanson Gauge
(Lincoln Dental, Cherry Hill, NJ, USA) directly on 1 month, 2
months, and 6 months old mice in a blind manner. Six
measurements were taken on each calvaria with three on each
side of parietal bone.
Femoral biomechanical testing
The four‐point bending test was performed as described
previously.(52,53) Femora were loaded in the anterior–posterior
direction so that the posterior side of the bone was in tension
and the anterior side was in compression. In brief, each bone was
tested on a specially adapted MTS Servo‐Hydraulic Testing
Machine (MTS Systems, Eden Prairie, MN, USA) that includes a
substructure to test mouse bones. Tests were conducted at a
constant rate of displacement equal to 0.5mm/second. Load
from a high‐resolution load cell and displacement from a linear
variable differential transformer were directly acquired in a
microcomputer. Utilizing algorithms developed in MatLab, the
load‐deformation data were analyzed for a variety of mechanical
property measures. All bones were tested while moist and at
room temperature. The following calculationsweremade: 1) load
to failure (yield load and ultimate load); 2) bending stiffness,
determined from a linear regression performed on the “pre‐
yield” portion of the load‐displacement curve (the term “yield” is
used here to refer to the point in the test when the load‐
displacement curve departs from a relatively linear course by
10%); 3) energy to failure.
Histomorphometry
Static and dynamic histomorphometry were performed as
described previously.(54,55) For dynamic histomorphometry,
mice were given intraperitoneal injections of calcein (10mg/kg)
and xylenol orange (90mg/kg) 6 days and 2 days, respectively,
before euthanization, and the measurement was made at
femur cortical bone. All static and dynamic parameters were
measured according to the Report of the American Society of
Bone and Mineral Research Histomorphometry Nomenclature
Committee.(56)
Primary calvarial osteoblast isolation and culture
Calvarial cells were isolated from 1‐ to 3‐day‐old transgenic mice.
After removal of sutures, parietal bones of calvariae were
subjected to four sequential digestions. The ﬁrst two digestions
were in an enzyme mixture containing 1mg/mL collagenase A
(Roche, Indianapolis, IN, USA) and 2mg/mL Dispase II (Roche) at
37°C on a rocking platform. The last two digestions were in an
enzyme mixture containing 2mg/mL collagenase A and 2mg/
mL Dispase II. Cell fractions (3 to 4) were collected and enzyme
activity was stopped by addition of an equal volume of a
modiﬁed essential medium (a‐MEM; Gibco by Life Technologies,
Grand Island, NY, USA) containing 10% heat‐inactivated fetal
bovine serum (FBS; HyClone, Thermo Scientiﬁc, Waltham, MA,
USA; SH30070.03), 100U/mL of penicillin, and 100mg/mL of
streptomycin (Gibco BRL, Grand Island, NY, USA). The fractions
were centrifuged, resuspended in a‐MEM containing 10% heat‐
inactivated FBS, and ﬁltered through a 70‐mm cell strainer. Cells
were plated in a density of 1.9 to 2.4 104 cells/cm2 in 6‐cm dish
in a‐MEM containing 10% heat‐inactivated FBS. Twenty‐four
hours later, the medium was changed. Three days later, the cells
were trypsinized and plated at a density of 1.5 104 cells/cm2 in
35‐mm culture plates in a‐MEM containing 10% FBS. For
autophagy ﬂux experiments, the lysosomal inhibitor NH4Cl
(30mM) or Chloroquine (100mM) were added to cells for
indicated length. For differentiation experiments, the medium
was changed 3 days later and thereafter every 2 days. At 1 week
of culture, the medium was changed to differentiation medium
(a‐MEM containing 10% FBS, 50mg/mL of ascorbic acid, and
4mM of beta‐glycerophosphate). In some of the differentiation
experiments, autophagy inhibitor 3‐MA (2mM) or Chloroquine
(5mM) was added to the culture from day 4 to day 21. The
autophagy inhibitor concentration was selected by their
effectiveness in inhibiting the basal autophagy in primary
calvarial osteoblasts.
LC3 conversion and turnover assay(57)
Primary calvarial osteoblasts were cultured in a‐MEM containing
10% heat‐inactivated FBS. To determine the steady‐state levels
of LC3II expression, the cells were treated with or without
lysosomal inhibitor, NH4Cl (30mM), for the indicated time. Cell
lysates were subjected to immunoblot analysis with an anti‐LC3
antibody. For turnover assay, the starved cells were treated with
or without Chloroquine (100mM) for 3 hours. The difference in
LC3‐II levels between samples with andwithout Chloroquine was
compared.
Bone marrow culture
Femurs and tibias from 6‐ to 8‐week‐old mice were dissected
from surrounding tissues. The epiphyseal growth plates were
removed and marrow collected by ﬂushing with serum‐free a‐
MEM containing 100U/mL penicillin and 100mg/mL streptomy-
cin with a 25‐gauge needle. Cells were plated in a density of
1 106 cells/cm2 in 35‐mm culture plates in a‐MEM containing
10% heat‐inactivated FBS. Half of the medium was changed on
day 3. On day 7, the medium was changed to differentiation
medium (a‐MEM containing 10% FBS, 50mg/mL of ascorbic acid,
and 8mMof beta‐glycerophosphate) and thereafter themedium
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was changed every 2 days until day 21. In some of the
differentiation experiments, autophagy inhibitor 3‐MA (2mM) or
Chloroquine (15mM) was added to the culture from day 3 to day
7 or from day 10 to day 21 as indicated. The autophagy inhibitor
concentration was selected by their effectiveness in inhibiting
the basal autophagy in mouse bone marrow osteoblasts. In
another set of differentiation experiments, FAK inhibitor, PF‐
573,228,(58) or FAK, Pyk2 dual inhibitor, PF‐562,271(59) (generous-
ly provided by Pﬁzer, Inc., New York, NY, USA), was added to the
culture from day 7 to day 21 at the pharmacologically effective
concentration of both 1mM and 5mM.
Histochemical analysis of cell cultures
Histochemical staining for ALP activity was performed using a
commercially available kit (86‐R Alkaline Phosphatase; Sigma
Diagnostics, Inc., St. Louis, MO, USA) according to the
manufacturer’s instructions. Mineralization was assessed using
modiﬁed Alizarin red (AR‐S) staining method. Brieﬂy, cells were
ﬁxed for 1 hour with ice‐cold 70% ethanol and washed with
water. Then the cells were stained with 40mM AR‐S, pH 4.2, at
room temperature for 10 minutes with rotation. The unbound
AR‐S were washed with water. To quantify the staining, 10% w/v
cetylpyridinium chloride (CPC) was added to elute the bound AR‐
S for 30 minutes at room temperature. Aliquots of these AR‐S
extracts were then diluted (in 10% CPC) and the concentration
determined by absorbance measurement at 562 nm on a plate
reader.
Starvation
For starvation, cells were washed with amino acid‐free Earle’s
balanced salt solution (EBSS; HyClone, SH30029.02) without FBS
(starvation medium) and incubated with the same medium. The
cells were starved 15 to 60 minutes for steady state autophagy
activity assay, 3 hours for autophagy ﬂux assay and GFP‐LC3
puncta assay, and 6 hours for transmission electron microscopy
examination.
Transmission electron microscopy
Samples were prepared as described previously with minor
modiﬁcation.(34) In brief, cells were ﬁxed in 2.5% glutaraldehyde
in 0.1M Sorensen’s buffer, pH 7.4, overnight at 4°C. They were
then postﬁxed in 1% osmium tetroxide and rinsed in double
distilled water and then stained with aqueous 1% uranyl acetate
for 1 hour. The samples were dehydrated in ethanol, rinsed two
times in propylene oxide, and embedded in epoxy resin. They
were ultrathin‐sectioned at 70 nm in thickness and stained with
uranyl acetate and lead citrate. The sections were examined and
recorded as described previously.(34,40) In brief, 37 to 46 sections
per group were randomly chosen to measure the mitochondria
size, number, and cytoplasmic area. Mitochondria number was
normalized by cytoplasmic area. Mitochondria size was the
average of 312 to 476 individual mitochondria.
Western blot analysis
Protein extracts were prepared from calvaria, heart, liver, growth
plate at distal femur, and proximal tibia of neonatal mice, femur
(after bone marrow ﬂushing), heart, liver of 1‐month‐old mice,
primary calvarial osteoblasts isolated from neonatal mice
(between at birth and postnatal day 3), and mouse embryonic
ﬁbroblast (MEF) cells. Cells and tissues were lysed using NP40
lysis buffer (pH 8.0 Tris‐HCl 20mM, NaCl 137mM, 1% NP40, 10%
glycerol, Na3VO4 1mM), and protein extracts were analyzed by
8% (FIP200, vinculin), 10% (P62), and 18% (LC3) SDS‐PAGE and
blotted onto PVDF membrane (Millipore, Billerica, MA, USA,
IPVH00010). Membranes were incubated with rabbit anti‐RBCC1
(FIP200) antibody (Proteintech, Chicago, IL, USA, 17250‐1‐AP),
rabbit anti‐P62 antibody (Enzolife Science, Farmingdale, NY, USA,
BML‐PW9860‐0100), mouse anti‐LC3 antibody (Nanotools,
Germany, NT‐0231‐100), or mouse anti‐vinculin antibody
(Sigma‐Aldrich, V4505) followed by horseradish peroxidase‐
conjugated secondary antibody (goat anti‐rabbit, Thermo
Scientiﬁc, 31460, and goat anti‐mouse, Jackson ImmunoRe-
search [West Grove, PA, USA], 115‐035‐072) and developed with
HPR substrate ECL (Millipore, WBKL S0500).
Immunofluorescence and fluorescence microscopy
Immunoﬂuorescent staining was performed as described
previously.(41) Anti‐Ki67 antibody was purchased from Spring
Bioscience (Pleasanton, CA, USA, M3062). Primary calvarial
osteoblasts isolated from GFP‐LC3 transgenic mice were
observed directly with a ﬂuorescence microscope (Olympus
BX51, Japan). The ﬂuorescent images were taken with Olympus
DP70 camera. The same exposure time was used in the same
experiment when pictures were taken.
RNA extraction and qRT‐PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. For qRT‐PCR
analyses, equal amounts of RNA were reverse‐transcribed by
SuperScript III ﬁrst‐strand synthesis system (Invitrogen) with
oligo(dT) as a primer, and then the resulting cDNA templates
were subjected to qRT‐PCR using the SYBR Green PCR Core
reagents system (Qiagen, Valencia, CA, USA) with the following
primers: ALP (alkaline phosphatase), BSP (bone sialoprotein),
OCN (osteocalcin), Osx (osterix), and 18SRNA. Primer sequences
are listed in Supplemental Methods.
Statistical analysis
Mann‐Whitney test was used to compare two test groups, and
differences were considered signiﬁcant for p< 0.05.
Results
Autophagy is activated during osteoblast nodule
formation and differentiation
As a ﬁrst step to test whether autophagy plays a role in osteoblast
differentiation, we assessed the dynamic autophagy activation
during osteoblast differentiation. First, we determined the
autophagy ﬂux by measuring the conversion of the cytosolic
form of LC3 (LC3‐I) to the autophagosome‐bound form of LC3
(LC3‐II) in the absence and presence of a lysosomal inhibitor,
NH4Cl, with lysate collected at different differentiation stages
(Fig. 1A and Supplemental Fig. S1). LC3‐II was detected in the
Journal of Bone and Mineral Research FIP200 IN BONE DEVELOPMENT AND OSTEOBLAST DIFFERENTIATION 2417
presence but not in the absence of NH4Cl and its level increased
with time (Fig. 1A), suggesting that autophagy ﬂux increases in
the differentiation process. In agreement with an increase in
autophagy ﬂux, we observed decreased expression of p62, a
selective autophagy substrate at a later differentiation time
point. Second, we examined GFP‐LC3 puncta, representing
autophagosome formation, during differentiation with primary
calvarial osteoblasts isolated from neonatal GFP‐LC3 mice.(46)
There were few cells that had positive GFP puncta before cells
reached conﬂuence, suggesting a low steady‐state autophagy.
However, GFP puncta dramatically increased after osteoblasts
reached conﬂuence (Fig. 1B), suggesting a much higher steady‐
state autophagy in osteoblasts during the cell cluster/nodule
formation process. Of note, we performed GFP puncta and LC3‐II
conversion experiments at the indicated time points 2 hours
after fresh medium changes to avoid the potential confounding
factor of nutrient deprivation in long‐term cultures. As a control,
we replenished nutrient medium for 2 hours in previously
starved subconﬂuent cultures and observed the complete
disappearance of GFP‐LC3 puncta (Fig. 1C). Third, we examined
the GFP‐LC3 punta formation in bone marrow stromal cell
culture from GFP‐LC3 mice.(46) In the same culture, we observed
very little GFP‐LC3 puncta in the cells that had not formed
cluster/colony (Fig. 1D1). However, there were numerous GFP‐
Fig. 1. Autophagy is activated during osteoblast differentiation. (A) Lysates isolated fromprimary calvarial osteoblasts at indicated different differentiation
stages with or without 2‐hour 30‐mMNH4Cl treatment were analyzed byWestern blotting using anti‐LC3 (top), anti‐p62 (middle) or anti‐vinculin (bottom)
antibodies. Graph on the right shows the quantiﬁcation of LC3‐II expression (normalized to vinculin expression). p< 0.05, n¼ 3. (B) Primary calvarial
osteoblasts were isolated from GFP‐LC3 transgenic mice, ﬁxed, and analyzed under ﬂuorescent microscope at indicated day after plating. (C) Primary
calvarial osteoblasts isolated fromneonatal GFP‐LC3 transgenicmicewere cultured in complete or starvationmedium for 2 hours or starvationmedium for
2 hours followed by 2‐hour completemediumat day 2 cultures before having reached conﬂuence. The cells were then ﬁxed, stainedwithDapi, and subject
to ﬂuorescent microscope analysis. (D) Bone marrow cells were isolated from 6‐ to 8‐week‐old GFP‐LC3 transgenic mice and subject to osteogenic
differentiation until day 11. D1 shows the isolated osteoblast like cells in the culture. D2 shows the slightly condensed osteoblast‐like cell nodule. D3 shows
the highly condensed osteoblast‐like cell nodule. The data shown were the representatives of at least three independent experiments.
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LC3 puncta in the cells that were undergoing cluster/nodule
formation (Fig. 1D2) and mineralization (Fig. 1D3). Altogether,
these data demonstrated that there is higher level of steady‐state
autophagy and autophagic ﬂux during osteoblast nodule
formation and differentiation, suggesting an important role of
autophagy in this process.
Ablation of FIP200 in osteoblasts leads to autophagy
deficiency
To assess the physiological signiﬁcance of autophagy activation
in osteoblasts, we generated conditional knockout mice to
delete FIP200, an essential mammalian autophagy gene in
osteoblasts. Brieﬂy, we mated ﬂoxed FIP200 (FIP200F/F) mice(43)
with Osx‐Cre transgenic mice(44) to generate FIP200F/F;Osx‐Cre
mice (designated as Osx‐CKO mice). Osx‐Cre mice express Cre
recombinase in osteoprogenitor cells committed to the osteo-
blast lineage.(44) Osx‐CKO and littermate control (FIP200F/F) mice
were born with a normal Mendelian ratio (data not shown). As a
ﬁrst step to characterize this mouse model, we evaluated
autophagy deﬁciency in FIP200‐null osteoblasts with several
complementary approaches. First, we examined the expression
of p62, a selective autophagy substrate in primary calvarial
osteoblasts isolated from Osx‐CKO mice. We observed increased
p62 expression in the osteoblasts isolated from Osx‐CKO mice
(designated as CKO cells or CKO osteoblasts) (Fig. 2A), suggesting
an autophagy defect in these cells. Of note, FIP200 was nearly
completely deleted in CKO osteoblasts, indicating that CKO cells
are FIP200‐null cells (Fig. 2A). Second, we examined the steady‐
state autophagy in CKO osteoblasts. In control cells, 30 and 60
minutes of amino acid and serum starvation induced LC3
conversion (Fig. 2B). In contrast, the starvation‐induced LC3
conversion was abolished in CKO cells. Third, we determined
autophagy ﬂux by LC3 turnover assay. Consistent with the role of
FIP200 in the initiation of autophagosome formation, LC3‐II
protein levels were signiﬁcantly lower under starvation and in
the presence of chloroquine in CKO cells compared with control
cells (Fig. 2C), indicating a defective autophagy ﬂux in CKO cells.
Fourth, we isolated primary calvarial osteoblasts from Osx‐CKO
and control mice bearing transgenic GFP‐LC3 and examined
GFP‐LC3 puncta formation after 2 hours of starvation. As
expected, we observed robust GFP‐LC3 puncta forming in
osteoblasts isolated from control mice, but this was absent in
osteoblast isolated from Osx‐CKO;GFP‐LC3 mice (Fig. 2D). Lastly,
to further conﬁrm the effects of loss of FIP200 on autophago-
some formation, we performed transmission electron micro-
scopic analysis. We detected autophagic vacuoles in about 30%
of the control osteoblasts (Fig. 2E, upper and lower left). In
contrast, autophagosome‐like structures were absent in CKO
cells (Fig. 2E, lower right).
To investigate the effects of starvation on osteoblast
mitochondria, the cells were subjected to 6‐hour starvation. In
control cells, mitochondria size increased (Fig. 2F), area
decreased (Fig. 2G), and number decreased (Fig. 2H) in response
to 6‐hour starvation, which is consistent with the notion that
mitochondria elongate and are partly degraded through
autophagy during starvation.(60) Interestingly, we found that
the mitochondria were enlarged in CKO cells (Fig. 2F) without
obvious difference in number (Fig. 2H). In CKO cells, the
mitochondria size did not increase but decreased instead in
response to starvation (Fig. 2F). Mitochondria area decrease (Fig.
2G) in these cells was proportional to the mitochondria size
decrease, suggesting that the mitochondria area decrease in
these cells was because of the mitochondria size decrease. In
contrast to the signiﬁcant decrease in mitochondria number in
control cells, there was no change in CKO cells in response to 6‐
hour starvation, further supporting the autophagy deﬁciency in
these cells. Taken together, these data suggested that FIP200‐
null osteoblasts were deﬁcient in autophagy.
FIP200 deletion leads to osteopenia in mice
Osx‐CKO and littermate control (FIP200F/F) mice were born with
similar body weight (Supplemental Fig. S2). However, by as early
as 1 week, both male and female Osx‐CKO mice weighed less
than controls. This weight differential was extended over the 6 to
12 months of observation. To investigate the effects of FIP200
deﬁciency on bone development, we ﬁrst evaluated deletion of
FIP200 by Western blotting of lysates from tissues of Osx‐CKO
and control neonatal mice. As shown in Supplemental Fig. S3, a
signiﬁcantly reduced level of FIP200was found in the calvaria but
not heart and liver samples from Osx‐CKO mice compared with
control mice, indicating efﬁcient and speciﬁc deletion of FIP200
as expected. We then performed whole mount skeleton staining
of newborn mice. Compared with control bones, Osx‐CKO mice
had no obvious developmental defects in major skeletal
elements including humerus, radius, and ulna (Supplemental
Fig. S4A), femur, tibia, and ﬁbula (Supplemental Fig. S4B), ribs and
vertebrae (Supplemental Fig. S4C), suggesting that bone
formation was not affected at this stage of development. Next,
we used micro‐CT to evaluate the effects of FIP200 deletion on
postnatal bone morphometry. Micro‐CT analysis revealed an
osteopenic phenotype in Osx‐CKO mice. In femur trabecular
bone of Osx‐CKO female mice, we observed a decrease (59%,
37%, and 53% at 1, 2, and 6 months, respectively) in trabecular
bone volume (BV/TV) (Fig. 3A), a decrease (52%, 33%, and 52% at
1, 2, and 6 months, respectively) in trabecular number (TbN) (Fig.
3B), a slight decrease (14% and 9% at 1 and 2 months,
respectively) in trabecular thickness (TbTh) (Fig. 3C), and an
increase (172%, 57%, and 129% at 1, 2, and 6 months,
respectively) in trabecular spacing (TbSp) (Fig. 3D). In femur
cortical bone of Osx‐CKO mice, we observed a decrease (17%,
23%, and 23% at 1, 2, and 6 months, respectively) in cortical
thickness (Fig. 3E), a decrease (16%, 9%, and 11% at 1, 2, and 6
months, respectively) in outer cortical bone perimeter (Fig. 3F),
and a decrease (16%, 6%, and 6% at 1, 2, and 6 months,
respectively) in inner cortical bone perimeter (Fig. 3G). Besides
the femurs, we performed micro‐CT analysis on 1‐month‐old L3
vertebrae and observed similar phenotype. There was a 34%,
21%, and 17% decrease in trabecular bone volume, trabecular
number, and trabecular thickness, respectively, in Osx‐CKO mice
(Supplemental Fig. S5). In addition to the endochondrally formed
bones, we also examined calvaria (intramembranous bone). The
calvarial thickness of CKO mice was signiﬁcantly decreased
compared with controls (Fig. 3H). Similar osteopenic phenotype
was observed in male mutant mice (Supplemental Fig. S6). To
Journal of Bone and Mineral Research FIP200 IN BONE DEVELOPMENT AND OSTEOBLAST DIFFERENTIATION 2419
Fig. 2. FIP200‐null osteoblasts are autophagy deﬁcient. (A) Primary calvarial osteoblasts were isolated from control or Osx‐CKO neonatal mice and
cultured in complete medium for 3 days. Cell lysates were subjected to immunoblot analysis with indicated antibodies. Graph on the right shows the
quantiﬁcation of p62 expression (normalized to vinculin expression). (B) Primary calvarial osteoblasts were cultured in complete medium or starvation
medium (serum and amino acid–free EBSS) for up to 60minutes. Cell lysates were subjected to immunoblot analysis with indicated antibodies. (C) Control
and FIP200‐null primary calvarial osteoblasts were cultured in the complete or starvationmedium for 3 hours with or without 100mMchloroquine. The cell
lysates were subjected to immunoblot analysis with indicated antibodies. Graph on the right shows the quantiﬁcation of LC3‐II expression with starvation
and chloroquine treatment. (D) Control and FIP200‐null primary calvarial osteoblasts isolated from mice expressing transgenic GFP‐LC3 were cultured in
complete medium or starvation medium for 120 minutes and then were observed directly with a ﬂuorescence microscope after ﬁxation. (E) Transmission
electron microscopic image of control and FIP200‐null primary calvarial osteoblasts. Arrows point to autophagosome‐like structure, arrowheads point to
autolysosome‐like structure, and asterisks indicatemitochondria. (F–H) Primary calvarial osteoblasts were isolated from neonatal control or Osx‐CKOmice.
Osteoblasts were cultured in complete or starvation medium for 6 hours and then ﬁxed and subjected to EM analysis and quantiﬁcation. (F) Mitochondria
size. #p< 0.001, n¼ 312–476 per group. (G) Mitochondria area per cytoplasmic area. p< 0.01, #p< 0.001, n¼ 37–46 per group. (H) Mitochondria number.
#p< 0.001, n¼ 37–46 per group. For F–H, the data were presented as mean SD. Western blotting and immunoﬂuorescence data shown were the
representative of three independent experiments. All experiments were performed before cells had reached conﬂuence.
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determine to what extent the low bone mass phenotype was
owing to theOsx‐Cre transgene itself, we analyzed the femur and
vertebrae L3 of Osx‐Cre mice and their littermate control mice.
Except the slightly decreased outer and inner femur cortical
perimeters, Osx‐Cremice had comparable cortical and trabecular
bone parameters comparedwith the control mice (Supplemental
Fig. S7), suggesting that the phenotype observed in Osx‐CKO
mice was largely because of the deletion of FIP200. To further
conﬁrm that the observed phenotype was indeed resulting from
the speciﬁc deletion of FIP200 in osteoblasts, we used other lines
of osteoblast‐targeting Cre transgenic mice, including Col3.6‐Cre
and Col2.3‐Cre(45) to delete FIP200 in osteoblasts and observed a
similar osteopenic phenotype in FIP200F/F;Col3.6‐Cre (Col3.6‐
CKO) mice (data not shown) and FIP200F/F;Col2.3‐Cre (Col2.3‐
CKO) mice (Supplemental Fig. S8A–D), highlighting the role of
FIP200 in osteoblast functions. As expected, signiﬁcantly reduced
level of FIP200 was found in femur but not heart and liver
samples from Col2.3‐CKO mice compared with control mice
(Supplemental Fig. S8E). In addition, FIP200‐null osteoblasts
isolated from Col2.3‐CKO mice demonstrated similar autophagy
Fig. 3. FIP200 deletion in osteoblasts leads to severe osteopenia in mice. (A–G) Trabecular and cortical parameters were determined by micro‐CT for the
femurs from 1‐month‐old (1M) to 6‐month‐old (6M) Osx‐CKO female mice: (A) bone volume/tissue volume (BV/TV); (B) trabebular number (TbN); (C)
trabecular thickness (TbTh); (D) trabecular spacing (TbSp); (E) cortical bone thickness; (F) cortical bone outer perimeter; (G) cortical bone inner perimeter.
(H) Calvarial bone thickness was directly measured with caliper. (I–N) Four‐point bending test with femurs: (I) yield load; (J) ultimate load; (K) stiffness; (L)
elastic energy; (M) plastic energy; and (N) energy to failure. For each group, n¼ 6–9, p< 0.05. Data are mean SD.
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deﬁciency (Supplemental Fig. S8F, G) as the cells isolated from
Osx‐CKO mice. Taken together, our data demonstrated that
FIP200 deletion in osteoblasts leads to compromised bone
development and decreased bone mass in mice.
To determine the extent to which FIP200 deletion would affect
the mechanical properties of bone, we tested the femurs of Osx‐
CKO and control mice by four‐point bending.(52) Femurs of
female mutant mice had decreased yield load (Fig. 3I), decreased
ultimate load (Fig. 3J), decreased stiffness (Fig. 3K), and
decreased elastic energy (Fig. 3L). In contrast, increased plastic
energy and total failure energy were noted in the 6‐month‐old
mutant group (Fig. 3M, N), whichmay be an adaptive response or
just a reﬂection of a change in the properties of the extracellular
matrix. Similar mechanical property changes were also found in
femurs of mutant male mice (Supplemental Fig. S3I–L).
Interestingly, the bones of the 6‐month‐old mutant male mice
had comparable yield load (Supplemental Fig. S3I) and ultimate
load (Supplemental Fig. S3J), which is consistent with the
comparable cortical bone thickness at this stage (Supplemental
Fig. S3E). Collectively, these data demonstrated that bones in
FIP200 mutant mice had signiﬁcantly altered mechanical
properties with decreased strength to resist fracture compared
with that of control mice.
Decreased bone formation and compromised osteoblast
terminal differentiation are responsible for the
osteopenic phenotype in Osx‐CKO mice
To determine the cellular mechanisms of FIP200 regulation on
bone metabolism, we performed histomorphometry on femurs
of Osx‐CKO and control mice. Consistent with micro‐CT
measurements, we observed decreased bone area (BA/TA)
(Fig. 4A), decreased trabecular number (TbN) (Fig. 4B), and
increased trabecular spacing (data not shown) in the femur of
Osx‐CKO mice. The osteoblast number (Nob/BS) (Fig. 4C) and
surface (ObS/BS) (Fig. 4D) but not the osteoclast number (NOc/
BS) (Fig. 4E) and surface (OcS/BS) (Fig. 4F) were reduced by the
deletion of FIP200 in Osx‐CKOmice. Dynamic histomorphometry
analysis revealed decreased bone formation in Osx‐CKO mice
(Fig. 4G–J). Collectively, these data suggest that compromised
osteoblast bone formation in vivo contributed to decreased
bone mass in Osx‐CKO mice.
Fig. 4. FIP200 deletion in osteoblasts leads to decreased bone formation. (A–F) Static histomorphometry for the femurs of 1‐month‐old female Osx‐CKO
and control mice: (A) trabecular bone area/tissue area (BA/TA); (B) trabecular bone number (TbN); (C) osteoblast number per bone surface (NOb/BS); (D)
osteoblast surface per bone surface (ObS/BS); (E) osteoclast number per bone surface (NOc/BS); (F) osteoclast surface per bone surface (OcS/BS). (G–J)
Dynamic histomorphometry for the femurs of 1‐month‐old female Osx‐CKO and control mice: (G) mineral apposition rate; (H) double labeling surface per
bone surface (dLS/BS); (I) decreased bone formation rate (BFR/BS); (J) representative calcein and xylenol orange double labeling image (5 days apart
between two labelings). p< 0.05, n¼ 5–7 per group.
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To further determine the mechanism responsible for the
decreased bone formation observed in Osx‐CKO mice, we
investigated the effect of FIP200 deletion on osteoblast
differentiation with two in vitro primary osteoblast culture
systems. First, we found that bone marrow stromal cells isolated
fromOsx‐CKOmice had compromised terminal differentiation as
shown by Alizarin Red staining (Fig. 5A, B). The expression levels
of osteoblast differentiation markers, including alkaline phos-
phates (ALP), bone sialoprotein protein (BSP), and osteocalcin
(OCN), as well as the osteoblast transcription factor Osterix (Osx)
were signiﬁcantly decreased in the CKO cultures (Fig. 5C). In
another complementary approach, we isolated bone marrow
stromal cells from FIP200F/F mice and infected them with an
adenovirus encoding Cre (Ade‐Cre) or Laz (Ade‐Laz) after 7 days’
culture (preosteoblastic colonies have been formed at this stage).
In the FIP200‐null group (Ade‐Cre), we observed compromised
mineralization (Fig. 5D, E), as well as decreased expression of
osteoblast differentiation markers (Fig. 5F), suggesting that
FIP200 plays a critical role at a later stage of differentiation. To
further conﬁrm the role of FIP200 in later osteoblast differentia-
tion stages, we isolated primary calvarial osteoblasts from
neonatal mice and cultured them in osteogenic medium.
Interestingly, we found that the early differentiation of FIP200‐
null calvarial osteoblasts was not compromised, as indicated by
the comparable alkaline phosphatase staining pattern (Fig. 5G)
and alkaline phosphatase (ALP, early osteoblast differentiation
marker) mRNA expression level (Fig. 5H). However, terminal
osteoblast differentiation was greatly compromised (Fig. 5I–K). In
addition, we observed similar differentiation defect in the
primary calvarial osteoblasts isolated from Col2.3‐CKO neonatal
mice (Supplemental Fig. S8H). Together, these data demonstrat-
ed that FIP200 deletion led to compromised osteoblast terminal
differentiation.
To determine whether the compromised differentiation was
the result of defective proliferation in FIP200‐null osteoblasts, we
used the primary calvarial osteoblast culture system to evaluate
the effects of FIP200 deletion on proliferation by Ki67 staining.
We found comparable Ki67‐positive cells in FIP200‐null and
control osteoblasts (Fig. 6A, B), indicating that FIP200 deﬁciency
did not affect primary calvarial osteoblast proliferation. Consis-
tent with the similarities in proliferation, there was a similar
increase in cell number in both groups during early culture
periods (Fig. 6C). However, CKO cell number increased much
slower after the cells reached conﬂuence (day 3 to day 4) and
there were signiﬁcantly fewer cells in CKO group at the end of 21
days of culture, suggesting the decreased osteoblast number
may be partly responsible for compromised mineralization.
However, after normalizing the calcium concentration shown in
Fig. 5J with cell numbers shown in Fig. 6C, there is still a 65%
decrease in mineralization in the CKO group, suggesting CKO
cells had compromised mineralization ability. Furthermore, at
late culture stages (day 21), as a result of condensational growth
and concomitant terminal differentiation, the control cells
formed large mineralized nodules. In contrast, FIP200‐null cells
formed fewer and much smaller nodules (Fig. 6D), suggesting a
defect in the nodule formation process. To determine the extent
to which FIP200 deletion affected the osteoblast nodule
formation ability, we evaluated the osteoblastic colony growth
in bone marrow culture with alkaline phosphatase staining. We
found that the size of alkaline phosphatase‐positive osteoblastic
colonies in the CKO group was similar to control cells at early
culture (day 7 and day 10) but was smaller at later stages of
culture (day 14) (Fig. 6E, G). Unexpectedly, we found there were
more alkaline phosphatase‐positive colonies in CKO cultures (Fig.
6E, F), which may be owing to the effects of FIP200 deletion on
early osteoblast progenitor cells. The total alkaline phosphatase‐
positive area was correspondingly larger in early CKO cultures
but not in late (day 14) cultures because of the signiﬁcantly
decreased colony size (Fig. 6H). The increased alkaline phospha-
tase‐positive osteoblasts in early culture and compromised
ability to grow in later culture associated with compromised
mineralization suggest an inability of osteoblasts to switch from
proliferation to mineralization upon FIP200 deletion. The
compromised ability to grow after having reached conﬂuence
in primary calvarial osteoblasts and defective colony growth in
bone marrow osteoblasts suggest that FIP200‐null osteoblasts
had a compromised ability to undergo the maturation process.
Taken together, the above data indicated that FIP200 deletion
adversely affected osteoblast nodule formation, leading to
defective terminal differentiation and compromised bone
formation ability.
Autophagy inhibitors mimic the effect of FIP200 deletion
on osteoblast differentiation
The aforementioned data demonstrated that autophagy is
activated during osteoblast differentiation (Fig. 1) and FIP200‐
null osteoblasts had nodule formation deﬁciency (Fig. 6).
Considering the positive role of autophagy in contributing to
the adaptive response of cells under stress, these data support
the notion that suppression of autophagy by FIP200 deletion is
responsible for the compromised osteoblast differentiation. To
test this hypothesis, we used two autophagy inhibitors, including
3‐methyladenine (3‐MA) and chloroquine, to determine whether
autophagy indeed plays an important role in osteoblast
differentiation.
Because we found that FIP200 deﬁciency had no effect on
osteoblastic colony size at day 10 bonemarrow culture but led to
decreased colony size at day 14 (Fig. 6E, G), we started to treat
bone marrow cells with 2mM 3‐MA or 15mM chloroquine at day
10 and examined its effect on early differentiation by alkaline
phosphatase staining at day 14 and mineralization by Alizarin
Red staining at day 21 (Fig. 7A). We found that both 3‐MA and
chloroquine treatment caused a decrease in the number of
alkaline phosphatase‐positive cells and led to smaller colony size
(Fig. 7A) compared with the control cultures, similar to the bone
marrow cells isolated from Osx‐CKO mice (Fig. 6E). Consistent
with the decrease in alkaline phosphatase staining–positive cells,
there was a signiﬁcant decrease in mineralization at day 21 (Fig.
7A), a mirror image of the bone marrow cells isolated from Osx‐
CKO mice (Fig. 5A, D). To determine whether the autophagy
inhibitors had any cytotoxic effect on bone marrow cells, bone
marrow cells were treatedwith 2mM3‐MAor 15mMchloroquine
at day 7 culture and then counted at day 9. No adverse effects of
inhibitor treatment on bone marrow cell number were observed
(Fig. 7B), suggesting the defective osteoblast differentiation in 3‐
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Fig. 5. FIP200 deletion compromises osteoblast terminal differentiation. (A–C) Bone marrow cells were collected from 6‐ to 8‐week‐old control or Osx‐CKO
miceandsubject toosteoblastdifferentiation: (A) RepresentativeAlizarinRedstaining imageat theendof21daysofosteogenicculture. (B)Quantiﬁedcalcium
concentrationfor thesamples in (A). (C)Osteoblastdifferentiationmarkerexpression inculturesshownin(A). (D–F)Bonemarrowcells fromFIP200F/Fmicewere
infectedwithadenovirusencodingCre(Ade‐Cre)orLaz(Ade‐Laz)after7daysofosteogenicculture: (D)RepresentativeAlizarinRedstainingimageat theendof
21daysofculture. (E)Quantiﬁedcalciumconcentration for thesamples in (D). (F)Osteoblastdifferentiationmarkerexpression in thecultures shown in (D). (G–K)
Primary calvarial osteoblast cultures: (G) Early osteoblast differentiationwas evaluatedbyAlkalinephosphatase staining at day 7 culture. (H) Early osteoblast
differentiationmarker (AlkalinephosphatasemRNA)wasdeterminedbyquantitativePCR. (I) RepresentativeAlizarinRedstaining imageat theendof21days
ofosteogenic culture. (J)Quantiﬁedcalciumconcentration for the samples in (I). (K)Osteoblastdifferentiationmarkerexpression incultures shown in (I). Data
are the representatives of three independent experiments with triplicates for each experiment. p< 0.05, n¼ 3 per group.
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MA‐ or chloroquine‐treated bone marrow culture was not
because of a cytotoxic effect. In addition, we treated the bone
marrow cells with 2mM 3‐MA from day 3 until day 7 (Fig. 7C) and
performed alkaline phosphatase staining at day 7. We found that
the 3‐MA treatment had no effect on the alkaline phosphatase‐
positive colony number and size (Fig. 7C). This indicated that 3‐
MA treatment had no effect on the early bonemarrow osteoblast
differentiation when the colony was small and not dense. The
comparable colony size at early culture and compromised late
differentiation in 3‐MA‐treated bone marrow osteoblasts
suggest the autophagy plays an important role in late osteoblast
differentiation. In addition to examining the effects of autophagy
inhibition on bone marrow osteoblast differentiation, we
determined the effects of autophagy inhibition on primary
Fig. 6. FIP200 deﬁciency compromises the osteoblast nodule formation. (A, B) Immunostaining with anti‐Ki67 antibody was performed in the primary
osteoblasts isolated from neonatal calvaria of Osx‐CKO and control mice. (A) Representative ﬂuorescent images. (B) Quantitative data of the Ki67‐positive
osteoblasts. (C, D) Primary calvarial osteoblasts were isolated from neonatal control or Osx‐CKO mice and cultured in osteogenic medium for 3 weeks: (C)
Cell numbers were counted at indicated time point. (D) Representative images showing the nodule formation at the end of 21 days of culture. Arrowheads
indicate the big nodules in control culture, and arrows indicate the small nodules in Osx‐CKO culture. (E–H) Bonemarrow cells were collected from 6‐ to 8‐
week‐old control or Osx‐CKO mice and subject to osteoblast differentiation: (E) Alkaline phosphatase staining at indicated time points. (F) Quantitative
Alkaline phosphatase‐positive (ALPþ) osteoblastic colony numbers at indicated time points as shown in (E). (G) Quantitative APþ osteoblastic colony size at
indicated time points as shown in (E). (H) Quantitative ALPþ area at indicated time points as shown in (E).
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Fig. 7. Inhibition of autophagy leads to compromised osteoblast differentiation. (A–C) Bone marrow cells were isolated from 6‐ to 8‐week‐old C57/BL6
mice and subject to osteogenic culture. (A) Diagram of the inhibitor treatment (2mM 3MA or 15mM chloroquine) scheme (late treatment) and the
representative images of Alkaline phosphatase staining and Alizarin Red staining results. (B) Bone marrow cells were treated with autophagy inhibitors at
indicated dose starting from day 7 for 2 days, and cell numbers were counted at day 9. (C) Diagramof the inhibitor treatment scheme (early treatment) and
the representative Alkaline phosphatase staining result. (D) Primary calvarial osteoblasts were isolated from neonatal C57/BL6 mice and subject to
osteogenic culture. Diagram shows the inhibitor treatment (2mM 3MA or 5mM chloroquine) scheme, and images show the representative Alkaline
phosphatase staining andAlizarin Red staining results. (E) Primary calvarial osteoblastswere isolated fromneonatal control or Osx‐Cremice and cultured in
osteogenic medium. For the control cells, one group was treated with 2mM 3MA and the other group was treated with 5mM chloroquine. Phase contrast
images were taken at indicated time points (D12 and D19 culture). Arrows point to the big nodule in control culture. Arrowheads point to the small nodule
in autophagy inhibitor‐treated culture. Scale bar¼ 0.25mm.
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calvarial osteoblast differentiation (Fig. 7D). Two mM 3‐MA or
5mM chloroquine treatment had no obvious adverse effect on
early osteoblast differentiation (Fig. 7D, lower left) but
compromised the terminal differentiation at day 21 culture
(Fig. 7D, lower right), similar to the observation in primary
calvarial osteoblasts isolated from Osx‐CKO mice (Fig. 5G, I).
Additionally, we found that the autophagy inhibitor treatment
did not affect the cell number increase at early culture (data not
shown), indicating that the defective osteoblast terminal
differentiation was not because of the cytotoxic effect. Lastly,
we determined the effects of autophagy inhibition on the
nodule‐formation ability of primary calvarial osteoblasts. Both 2‐
mM 3‐MA and 5‐mM chloroquine treatment negatively affected
condensed nodule formation, mimicking the effect of FIP200
deletion (Fig. 7E). Altogether, autophagy inhibition with both 3‐
MA and chloroquine recapitulated the effect of suppression of
autophagy by FIP200 deletion on osteoblast differentiation,
strongly supporting the notion that FIP200 regulates osteoblast
differentiation through its autophagy function.
Discussion
Autophagy, themajor intracellular degradation system, has been
implicated in many physiological and pathological processes. It
has gained attention recently as an essential contributor to
human health and disease.(1,16,61,62) Compared with our
understanding of the role of autophagy in many organs, little
is known about how autophagy regulates bone physiology and
disease. The global knockout of many autophagy genes in mice,
including Ambra1,(63) Atg5,(5) Atg7,(64) Beclin,(65) and FIP200,(43)
leads to early lethality, preventing us from studying the
physiological role of autophagy in bone development. In this
study, we overcame this limitation by generating FIP200
conditional KO mice with three different Cre transgenic mouse
lines targeting osteoblast lineage cells, including Osx‐Cre,(44)
Col3.6‐Cre, and Col2.3‐Cre.(45) A similar osteopenia phenotype
was observed in all transgenic lines, highlighting the important
role of FIP200 in bone development and osteoblast function. Our
data provide a rigorous and direct demonstration of the positive
role of autophagy in osteoblast differentiation.
As expected, we observed that FIP200‐null osteoblasts were
autophagy deﬁcient. However, in contrast to the reported
deformed mitochondria in Atg7‐deﬁcient hepatic cells(64) and
FIP200‐deﬁcient mammary tumor cells,(40) we did not notice
obvious mitochondria deformation in CKO cells, whereas we
found that the mitochondria size was increased in these cells.
This suggested a cell type–speciﬁc effect of autophagy
deﬁciency on mitochondria morphology. In response to 6‐hour
starvation, mitochondria size increased signiﬁcantly but the
mitochondria area decreased signiﬁcantly in control cells, which
is consistent with the recent ﬁnding that mitochondria elongate
during starvation.(60) Through fusion, mitochondria have bigger
size in an elongated form during starvation. In themeantime, the
mitochondria with smaller size are easier to be eliminated
through autophagy. We also found that mitochondria number in
control cells decreased greatly (46%) in response to 6‐hour
starvation, which is likely owing to both the elongation and
autophagic degradation of mitochondria. In CKO cells, the
mitochondria size did not increase but decreased instead. This
size decrease may be mediated through the autophagy function
of FIP200 or alternatively through the potential direct role of
FIP200 in mitochondria itself. The mitochondria number in CKO
cells was not changed in response to 6‐hour starvation,
suggesting that mitochondria were not degraded in these cells
through autophagy. However, it is important to note that
mitochondria could be degraded in CKO cells through other
autophagy‐independent mechanisms such as proteasomal
degradation machinery or as a consequence of induction of
the apoptotic pathway.(66)
The essential role of FIP200 in autophagy in many mammalian
cell types is well documented.(30–33,67) Our data demonstrated
the requirement of FIP200 in osteoblast autophagy. We also
showed that treatment with autophagy inhibitors recapitulated
the effects of FIP200 deletion on osteoblast nodule formation
and terminal differentiation. These data strongly suggest that
FIP200 regulates osteoblast function through its autophagy role.
However, it is still possible that FIP200 may regulate osteoblast
differentiation at least partially through its nonautophagic roles.
FIP200 was originally identiﬁed by our group as an inhibitor of
FAK and its related kinase Pyk2.(27,28) Because both FAK and Pyk2
have been shown to regulate osteoblast function,(68,69) this
raised the possibility that FIP200 regulates osteoblast differenti-
ation through FAK/Pyk2. However, it was shown that FAK does
not play an important role in osteoblast differentiation, although
it regulates bone healing.(68) On the other hand, it was shown
that Pyk2 can regulate osteoblast differentiation but it only has
the inhibitory effect on early osteoblast progenitor cells but not
on more mature primary calvarial osteoblast.(69) Our data clearly
showed that the effect of FIP200 deletion on osteoblast
differentiation was at later stage but not early stage. Therefore,
it is not likely that FIP200 regulates osteoblasts mainly through
Pyk2. We still cannot exclude the possibility that the increased
FAK and/or Pyk2 activity in FIP200‐null osteoblast may account at
least partly for the observed differentiation defect because
previous studies only examined the effect of FAK knockdown
(but not overexpression) on osteoblast differentiation. However,
we found that FAK inhibitor(58) and FAK, Pyk2 dual inhibitor(59)
failed to rescue the defective differentiation in FIP200 Osx‐CKO
bonemarrow culture, although the higher concentration of both
inhibitors negatively affected the osteoblast differentiation
(Supplemental Fig. S9), suggesting the osteoblast differentiation
defect in FIP200‐null cells was not because of increased FAK and/
or Pyk2 activity.
During development and differentiation, enhanced autopha-
gic degradation is often required to cope with the drastic cellular
and tissue remodeling.(1) Here, we report that autophagy is
activated during osteoblast nodule formation and differentiation
and suppression of autophagy by FIP200 deletion leads to
severely compromised bone formation with defective osteoblast
differentiation. Furthermore, the suppression of autophagy by
FIP200 deletion led to decreased osteoblastic colony size and
decreased osteoblast nodule size in bone marrow and primary
calvaria cultures, respectively. These data suggested an inability
of osteoblasts to switch from initial proliferation to mineraliza-
tion upon FIP200 deletion. During terminal differentiation
process, osteoblasts secrete abundant extracellular matrix with
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active protein synthesis. mTOR signaling is the major pathway to
regulate protein synthesis. Protein synthesis and autophagic
degradation are usually regulated in an opposite manner by
mTOR. Activated mTOR facilitates the protein synthesis and
inhibits autophagy.(70,71) However, it is recently reported that
protein degradation and synthesis may be spatially coupled in
certain cells that have increased protein secretion, such as
podocytes and differentiatingmacrophagy. It is delicately shown
that autophagy‐generated amino acids contribute to the mTOR
recruitment and activity.(72) Thus, the catabolic (autophagy)
machinery could augment the anabolic (mTOR) machinery and
facilitate the mass synthesis of secretory proteins. This raised the
interesting possibility that osteoblasts may utilize autophagy in
the samemanner to facilitate the robust protein synthesis, which
is crucial for their terminal differentiation. Furthermore, we
demonstrated that the autophagy inhibition by known autoph-
agy inhibitors mimicked the effects of FIP200 deletion on
osteoblast differentiation and nodule/colony formation ability in
vitro, supporting the hypothesis that FIP200 regulates osteoblast
differentiation through its autophagy role. Interestingly, the
suppression of autophagy either by FIP200 deletion or
administration of autophagy inhibitors did not affect early
osteoblast differentiation when the osteoblastic colony size is
relatively small and cells are not dense. This suggests the
development/differentiation stage–dependent role of autoph-
agy in osteoblast differentiation.
In CKO mice, we found that there was 57% BV/TV decrease in
younger (1 month) male mice, whereas there was only 39%
decrease in older (1 year) mice. The smaller difference at older
age may be explained by the decreased autophagy efﬁciency in
the wild‐type osteoblasts of older mice, similar to the
phenomenon observed in other cell types.(73) However, the
autophagy efﬁciency of osteoblasts from aged animal needs to
be determined to address this possibility. The alternative
possibility is that the bigger effect of FIP200 deletion on early
bone development may be owing to the higher requirement of
autophagy in active bone growth phase.
Our data demonstrated that autophagy deﬁciency in osteo-
blasts led to compromised osteoblast differentiation and
mineralization, and it may suggest that autophagy dysregulation
may be one causal factor for bone disease such as osteoporosis.
In line with the ﬁndings in our mouse models, a recent pathway‐
based genome‐wide association study identiﬁed the association
between regulation‐of‐autophagy pathway with human wrist
bone mineral density and osteoporosis.(20) It is generally
assumed that the autophagy level decreases as a result of
aging.(73) It is tempting to propose to increase autophagy to treat
aging‐associated osteoporosis. In fact, a recent attempt to
increase autophagy by inhibiting mTOR signaling pathway leads
to improved cognitive function in a mouse model of Alzheimer
disease.(74) Recently, a candidate therapeutic peptide that can
induce autophagy in vivo in peripheral tissues in adult mice was
identiﬁed.(75) Strikingly, this peptide can improve the clinical
outcome of mice with virus infection by enhancing autophagy.
This raises the interesting possibility that similar approaches
could be applied to bone disorders.
In conclusion, our studies identiﬁed an important role of
FIP200, an essential autophagy gene, in bone development in
several mouse models. We demonstrated that the ablation of
FIP200 in osteoblasts inhibited osteoblast differentiation
through negatively affecting osteoblast nodule formation and
mineralization ability. These results provide novel insight into the
regulation of bone development and osteoblast differentiation
by autophagy. However, there are still many unanswered
questions that need to be addressed: What are the detailed
molecular mechanisms bywhich autophagy regulates osteoblast
functions?What are the roles of autophagy in late postnatal bone
development? What are the roles of autophagy in bone disease
such as osteoporosis? How does aging affect the osteoblast
autophagy activity? Answers to these questions will greatly help
in better understanding the pathogenesis of bone diseases and
may reveal novel ways to treat age‐induced bone loss.
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